|
WO2021074423A2
|
|
Vaccine product
|
|
WO2021074286A2
|
|
Influenza virus vaccines and uses thereof
|
|
WO2021067785A1
|
|
Staphylococcus peptides and methods of use
|
|
WO2021064688A1
|
|
Adenovirus vectors and uses thereof
|
|
WO2021043869A1
|
|
Influenza virus vaccines and uses thereof
|
|
WO2020237052A1
|
|
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
WO2020229581A1
|
|
Methods for inducing a safe immune response against polio virus
|
|
WO2020229579A1
|
|
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
|
WO2020229577A1
|
|
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
|
WO2020216844A1
|
|
Recombinant influenza antigens
|
|
WO2020099383A1
|
|
Stabilized pre-fusion rsv f proteins
|
|
AU2019361253A1
|
|
Anti-synuclein antibodies
|
|
AU2019345942A1
|
|
Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
|
|
AU2019323115A1
|
|
Stabilized filovirus glycoprotein trimers
|
|
WO2020016394A1
|
|
Recombinant adenoviral vector expressing zika antigen with improved productivity
|
|
KR20200116105A
|
|
Binding molecule that specifically binds to tau
|
|
US2019231866A1
|
|
Methods for safe induction of cross-clade immunity against hiv infection in humans
|
|
AU2019212180A1
|
|
Influenza virus vaccines and uses thereof
|
|
EP3720490A1
|
|
Binding molecules that specifically bind to tau
|
|
CN111295449A
|
|
Adenovirus vectors and uses thereof
|
